Doximity (DOCS) Stock Forecast & Price Target

Compare

980 Followers

See the Price Targets and Ratings of:

All Analysts

Top Analysts

Premium

DOCS Analyst Ratings

Strong Buy

14 Buy

4 Hold

0 Sell

Based on 18 analysts giving stock ratings to

Doximity

in the past 3 months

TipRanks enables you to focus on the analyst rating consensus of all analysts or only the top performers in the past 3 months

DOCS Stock 12 Month Forecast

Average Price Target

$41.13

▲(62.31% Upside)

Based on 18 Wall Street analysts offering 12 month price targets for Doximity in the last 3 months. The average price target is $41.13 with a high forecast of $56.00 and a low forecast of $25.00. The average price target represents a 62.31% change from the last price of $25.34.

{"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex, -apple-system, BlinkMacSystemFont, Segoe UI, Roboto, Helvetica, Arial, sans-serif, Apple Color Emoji, Segoe UI Emoji, Segoe UI Symbol","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"24":"$24","71":"$71","35.75":"$35.8","47.5":"$47.5","59.25":"$59.3"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":56,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n\n  <span style=\"color:#199ca5\">$56.00</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":41.13,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n\n  <span style=\"color:#828080\">$41.13</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":25,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n\n  <span style=\"color:#912767\">$25.00</span>\n  </div></div>","useHTML":true}}],"tickPositions":[24,35.75,47.5,59.25,71],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"May<br/>2025","6":"Aug<br/>2025","9":"Nov<br/>2025","12":"Feb<br/>2026","25":"Feb<br/>2027"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,37.29,38.72923076923077,40.168461538461536,41.607692307692304,43.04692307692308,44.48615384615385,45.925384615384615,47.364615384615384,48.80384615384615,50.24307692307693,51.68230769230769,53.121538461538464,54.56076923076923,{"y":56,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,37.29,37.58538461538461,37.88076923076923,38.176153846153845,38.471538461538465,38.76692307692308,39.06230769230769,39.35769230769231,39.653076923076924,39.94846153846154,40.24384615384616,40.53923076923077,40.83461538461539,{"y":41.13,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,37.29,36.34461538461538,35.39923076923077,34.45384615384615,33.50846153846154,32.56307692307692,31.61769230769231,30.67230769230769,29.72692307692308,28.78153846153846,27.83615384615385,26.89076923076923,25.945384615384615,{"y":25,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":59.1,"date":1738368000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 17,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 17, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":70.5,"date":1740787200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 12,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 14, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":56.72,"date":1743465600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 13,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 13, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":58.07,"date":1746057600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 11,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 16, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":51.5,"date":1748736000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 14,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 19, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":58.38,"date":1751328000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 16,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 20, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":57.33,"date":1754006400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 22,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 18, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":67,"date":1756684800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 26,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 16, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":70.64,"date":1759276800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 33,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 16, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 3</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":66,"date":1761955200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 32,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 19, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 3</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":51.07,"date":1764547200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 34,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 19, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 3</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":44.28,"date":1767225600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 45,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 19, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":37.29,"date":1769904000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 89,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 26, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}

Highest Price Target$56.00

Average Price Target$41.13

Lowest Price Target$25.00

The highest, average, and lowest price target of all analysts. Click on ‘Top Analysts’ to focus on the best performers.

Detailed List of Analyst Forecasts

Ryan Halsted

RBC Capital

$44

Buy

73.64%

Upside

Reiterated

03/09/26

Analysts Are Bullish on These Healthcare Stocks: Cytokinetics (CYTK), Doximity (DOCS)

Elizabeth Anderson CFA

Evercore ISI

$30

Buy

18.39%

Upside

Reiterated

03/09/26

Analysts' Top Healthcare Picks: Revolution Medicines (RVMD), Incyte (INCY)

Alexei Gogolev

J.P. Morgan

$40→$33

Hold

30.23%

Upside

Reiterated

02/20/26

Doximity price target lowered to $33 from $40 at JPMorganDoximity price target lowered to $33 from $40 at JPMorgan

Jessica Tassan

Piper Sandler

$40→$42

Buy

65.75%

Upside

Reiterated

02/20/26

Doximity price target raised to $42 from $40 at Piper SandlerDoximity price target raised to $42 from $40 at Piper Sandler

Allen Lutz

Bank of America Securities

$56

Buy

120.99%

Upside

Reiterated

02/12/26

Analysts Offer Insights on Healthcare Companies: Doximity (NYSE: DOCS), Atricure (NASDAQ: ATRC) and Inspire Medical Systems (NYSE: INSP)

Jailendra Singh

Truist Financial

―

Buy

―

Reiterated

02/12/26

Analysts' Opinions Are Mixed on These Healthcare Stocks: Madrigal Pharmaceuticals (NASDAQ: MDGL), Doximity (NYSE: DOCS) and Humana (NYSE: HUM)

Glen Santangelo

Barclays

$63→$38

Buy

49.96%

Upside

Reiterated

02/10/26

Analysts Are Bullish on These Healthcare Stocks: Doximity (DOCS), Quest Diagnostics (DGX)

Steven Valiquette

Mizuho Securities

$45→$34

Hold

34.18%

Upside

Reiterated

02/10/26

Mizuho Securities Remains a Hold on Doximity (DOCS)

Richard Close

Canaccord Genuity

$48→$34

Buy

34.18%

Upside

Upgraded

02/09/26

Canaccord Genuity Sticks to Its Hold Rating for Doximity (DOCS)

David Roman

Goldman Sachs

$46→$34

Hold

34.18%

Upside

Reiterated

02/09/26

Doximity price target lowered to $34 from $46 at Goldman SachsDoximity price target lowered to $34 from $46 at Goldman Sachs

Craig Hettenbach

Morgan Stanley

$65→$49

Buy

93.37%

Upside

Reiterated

02/06/26

Morgan Stanley Sticks to Its Buy Rating for Doximity (DOCS)

Ryan Daniels

William Blair

―

Buy

―

Reiterated

02/06/26

Doximity: Resilient Fundamentals and AI-Driven Growth Support Buy Rating Despite Temporary Pharma Budget Delays

Scott Schoenhaus

KeyBanc

$60→$38

Buy

49.96%

Upside

Reiterated

02/06/26

Doximity price target lowered to $38 from $60 at KeyBancDoximity price target lowered to $38 from $60 at KeyBanc

David Larsen

BTIG

$80→$50

Buy

97.32%

Upside

Reiterated

02/06/26

Doximity: Rebounding Pharma Momentum, Emerging AI Upside, and Attractive Valuation Support Renewed Growth Buy Thesis

Ryan MacDonald

Needham

$55

Buy

117.05%

Upside

Reiterated

02/06/26

Buy Rating on Doximity: Near‑Term Timing Headwinds Create an Attractive Entry Point Amid Durable Growth and Margin Strength

Analyst Type

Any

Human Analysts

Ranks

Any

Analyst Rating

Any

Upside/ Downside

Any

Action

Any

Ryan Halsted

RBC Capital

$44

Buy

73.64%

Upside

Reiterated

03/09/26

Analysts Are Bullish on These Healthcare Stocks: Cytokinetics (CYTK), Doximity (DOCS)

Elizabeth Anderson CFA

Evercore ISI

$30

Buy

18.39%

Upside

Reiterated

03/09/26

Analysts' Top Healthcare Picks: Revolution Medicines (RVMD), Incyte (INCY)

Alexei Gogolev

J.P. Morgan

$40→$33

Hold

30.23%

Upside

Reiterated

02/20/26

Doximity price target lowered to $33 from $40 at JPMorganDoximity price target lowered to $33 from $40 at JPMorgan

Jessica Tassan

Piper Sandler

$40→$42

Buy

65.75%

Upside

Reiterated

02/20/26

Doximity price target raised to $42 from $40 at Piper SandlerDoximity price target raised to $42 from $40 at Piper Sandler

Allen Lutz

Bank of America Securities

$56

Buy

120.99%

Upside

Reiterated

02/12/26

Analysts Offer Insights on Healthcare Companies: Doximity (NYSE: DOCS), Atricure (NASDAQ: ATRC) and Inspire Medical Systems (NYSE: INSP)

Jailendra Singh

Truist Financial

―

Buy

―

Reiterated

02/12/26

Analysts' Opinions Are Mixed on These Healthcare Stocks: Madrigal Pharmaceuticals (NASDAQ: MDGL), Doximity (NYSE: DOCS) and Humana (NYSE: HUM)

Glen Santangelo

Barclays

$63→$38

Buy

49.96%

Upside

Reiterated

02/10/26

Analysts Are Bullish on These Healthcare Stocks: Doximity (DOCS), Quest Diagnostics (DGX)

Steven Valiquette

Mizuho Securities

$45→$34

Hold

34.18%

Upside

Reiterated

02/10/26

Mizuho Securities Remains a Hold on Doximity (DOCS)

Richard Close

Canaccord Genuity

$48→$34

Buy

34.18%

Upside

Upgraded

02/09/26

Canaccord Genuity Sticks to Its Hold Rating for Doximity (DOCS)

David Roman

Goldman Sachs

$46→$34

Hold

34.18%

Upside

Reiterated

02/09/26

Doximity price target lowered to $34 from $46 at Goldman SachsDoximity price target lowered to $34 from $46 at Goldman Sachs

Craig Hettenbach

Morgan Stanley

$65→$49

Buy

93.37%

Upside

Reiterated

02/06/26

Morgan Stanley Sticks to Its Buy Rating for Doximity (DOCS)

Ryan Daniels

William Blair

―

Buy

―

Reiterated

02/06/26

Doximity: Resilient Fundamentals and AI-Driven Growth Support Buy Rating Despite Temporary Pharma Budget Delays

Scott Schoenhaus

KeyBanc

$60→$38

Buy

49.96%

Upside

Reiterated

02/06/26

Doximity price target lowered to $38 from $60 at KeyBancDoximity price target lowered to $38 from $60 at KeyBanc

David Larsen

BTIG

$80→$50

Buy

97.32%

Upside

Reiterated

02/06/26

Doximity: Rebounding Pharma Momentum, Emerging AI Upside, and Attractive Valuation Support Renewed Growth Buy Thesis

Ryan MacDonald

Needham

$55

Buy

117.05%

Upside

Reiterated

02/06/26

Buy Rating on Doximity: Near‑Term Timing Headwinds Create an Attractive Entry Point Amid Durable Growth and Margin Strength

Stocks with the Highest Top Analyst Consensus in the Healthcare Sector

xxx

Find stocks in the Healthcare sector that are highly recommended by Top Performing Analysts.

Best Analysts Covering Doximity

3 Months

xxx

Success Rate

8/16 ratings generated profit

Average Return

+2.44%

upgraded a xxx

rating 29 days ago

Copying xxxxxxxxxxxxxxxxxx

trades and holding each position for 3 Months would result in 50.00% of your transactions generating a profit, with an average return of +2.44% per trade.

1 Year

Allen LutzBank of America Securities

Success Rate

6/13 ratings generated profit

Average Return

-13.55%

reiterated a buy rating 26 days ago

Copying Allen Lutz's trades and holding each position for 1 Year would result in 46.15% of your transactions generating a profit, with an average return of -13.55% per trade.

2 Years

xxx

Success Rate

9/16 ratings generated profit

Average Return

+37.86%

upgraded a xxx

rating 29 days ago

Copying xxxxxxxxxxxxxxxxxx

trades and holding each position for 2 Years would result in 56.25% of your transactions generating a profit, with an average return of +37.86% per trade.

The Best Analyst Covering tool allows you to follow the analysts who have the best success rates and average returns on a specific stock. Only analysts that gave a Buy or Sell rating on the stock in the past 12 months are eligible for inclusion in this tool. Follow the analysts of your choice to receive real-time updates when they publish a new rating.

DOCS Analyst Recommendation Trends

Rating

Oct 25

Nov 25

Dec 25

Jan 26

Feb 26

Strong Buy

Buy

Hold

Sell

Strong Sell

total

116

In the current month, DOCS has received 89 Buy Ratings, 26 Hold Ratings, and 1 Sell Ratings. DOCS average Analyst price target in the past 3 months is 41.13.

Each month's total comprises the sum of three months' worth of ratings.

DOCS Financial Forecast

DOCS Earnings Forecast

Next quarter’s earnings estimate for DOCS is $0.28 with a range of $0.22 to $0.33. The previous quarter’s EPS was $0.46. DOCS beat its EPS estimate ― of the time in the past 12 months, while its overall industry beat the EPS estimate 57.43% of the time in the same period. In the last calendar year DOCS has Performed in-line its overall industry.

DOCS Sales Forecast

Next quarter’s sales forecast for DOCS is $144.39M with a range of $143.18M to $154.00M. The previous quarter’s sales results were $185.05M. DOCS beat its sales estimates ― of the time in past 12 months, while its overall industry beat sales estimates 49.17% of the time in the same period. In the last calendar year DOCS has Performed in-line its overall industry.

DOCS Stock Forecast FAQ

What is DOCS’s average 12-month price target, according to analysts?

Based on analyst ratings, Doximity, Inc.’s 12-month average price target is 41.13.

What is DOCS’s upside potential, based on the analysts’ average price target?

Doximity, Inc. has 62.31% upside potential, based on the analysts’ average price target.

Can I see which stocks the top-ranking analysts are rating?

Yes, go to the Analysts’ Top Stocks tool to see stocks with a Strong Buy or Strong Sell analyst rating consensus, according to the top performers.

How can I follow the stock ratings of top Wall Street analysts?

Head over to our Expert Center to see a list of the top 100 Wall Street analysts and follow the analysts of your choice. Visit their profiles for more details about their stock ratings and see how they perform on a stock-by-stock basis.

Is DOCS a Buy, Sell or Hold?

Doximity, Inc. has a consensus rating of Strong Buy which is based on 14 buy ratings, 4 hold ratings and 0 sell ratings.

What is Doximity, Inc.’s price target?

The average price target for Doximity, Inc. is 41.13. This is based on 18 Wall Streets Analysts 12-month price targets, issued in the past 3 months.
The highest analyst price target is $56.00 ,the lowest forecast is $25.00. The average price target represents 62.31% Increase from the current price of $25.34.

What do analysts say about Doximity, Inc.?

Doximity, Inc.’s analyst rating consensus is a Strong Buy. This is based on the ratings of 18 Wall Streets Analysts.

How can I buy shares of DOCS?

Open a brokerage account, see exclusive account opening deals on our Best Online Brokers page.

Doximity (DOCS) Stock Forecast & Price Target

DOCS Analyst Ratings

DOCS Stock 12 Month Forecast

Average Price Target

Detailed List of Analyst Forecasts​

Best Analysts Covering Doximity

DOCS Analyst Recommendation Trends

DOCS Financial Forecast

DOCS Earnings Forecast

DOCS Sales Forecast

DOCS Stock Forecast FAQ

Detailed List of Analyst Forecasts